Seite auswählen

The U.S. pharmaceutical company Bristol-Myers Squibb (BMS) has experienced a slump in sales due to the amortisation of billions of dollars, seeing them slip into the red. The bottom line is that the Group recorded a loss of $711 million, contrasting to last year’s profit of $969 million.

And in terms of revenue, that also went downhill: after $5.35 billion in the prior year, BMS sales of $3.73 billion in the third quarter of 2012 are 30 percent less.

 

[ilink url=“http://news.bms.com/press-release/financial-news/bristol-myers-squibb-reports-third-quarter-2012-financial-results“] Link zur Quelle (BMS)[/ilink]